Gilead Sciences Inc. (GILD)

NASDAQ: GILDHealthcareDrug Manufacturers - GeneralUSD

146.85+2.62 (+1.82%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

After hours: 146.85 0.00%

GILD stock chart

Technical analysis

Key statistics

All statistics

Market cap: $182.09B
P/E (TTM): —
Forward P/E: 14.85
EPS (TTM): -$2.65
Dividend yield: 2.19% ($3.22)
Ex-dividend date: Sep 15, 2026
52-week range: 114.02 – 157.29
Day range: 144.85 – 148.60
Volume / Avg: 3.96M / 6.06M
Beta: —
Shares outstanding: 1.24B
Next earnings: Oct 29, 2026

52-week range

$114.02$157.29

GILD stock today

Gilead Sciences (GILD) closed at $146.85 on Oct 7, up 1.82% (+$2.62), versus the S&P 500's 0.22% decline. At this level, GILD sits in the middle of its 52-week range of $114.02 to $157.29: 6.6% below the high, set on Feb 11, 2026 and 28.8% above the low. GILD is up 20.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 26.2%.

Gilead Sciences has posted a net loss over the last twelve months (EPS of -$2.65), so its P/E ratio is not meaningful. Gilead Sciences's next earnings report is expected on Oct 29, 2026. Gilead Sciences pays an annual dividend of $3.22 per share, a 2.19% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Gilead Sciences

Company profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Mr. Daniel Patrick O'Day
Headquarters: Foster City, CA
Employees: 17,000
IPO year: 1992
Website: gilead.com

Financial highlights

Full financials

In fiscal 2025, Gilead Sciences generated $29.44 billion in revenue, up 2.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $8.51 billion (+1672.9% year over year), for a net margin of 28.9% versus a median of 16.8% in the prior 5 years. Gross margin was 78.8% (up from 78.3%) and operating margin 34.0%.

Gilead Sciences annual revenue, net income and EPS
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$29.44B	$28.75B	$27.12B	$27.28B	$27.30B
Growth	+2.40%	+6.04%	-0.60%	-0.09%	+10.60%
Net income	$8.51B	$480.00M	$5.67B	$4.59B	$6.22B
EPS (diluted)	$6.78	$0.38	$4.50	$3.64	$4.93

Analyst forecast

Forecast

Consensus (28 analysts)

buy

Avg. price target

$159.27+8.46%

Strong buy 6
Buy 16
Hold 5
Sell 0
Strong sell 1

Target range

Low $123.00High $180.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history

Next report: Oct 29, 2026
EPS estimate: $2.15
Last reported (Q2 2026): Aug 6, 2026
EPS actual vs est.: $-8.45 vs —

Dividends

Dividend history

Annual dividend: $3.22
Dividend yield: 2.19%
Last payment: $0.82
Ex-dividend date: Sep 15, 2026

GILD news

All GILD news

Gilead Sciences peers

Healthcare sector

GILD peer companies
Company	Price	% Chg	Market cap	P/E	Compare
NVONovo Nordisk A/S	38.26	+1.95%	$168.89B	9.4	vs GILD
PFEPfizer Inc.	27.99	+1.78%	$159.53B	36.8	vs GILD
AMGNAmgen Inc.	413.08	+2.60%	$223.32B	25.7	vs GILD
BMYBristol-Myers Squibb Company	59.68	+0.15%	$121.91B	13.1	vs GILD
AZNAstraZeneca PLC	160.13	+0.96%	$248.35B	23.9	vs GILD
SNYSanofi ADS	40.20	+1.62%	$96.32B	21.2	vs GILD
GSKGSK plc ADR	47.02	+0.89%	$94.20B	14.8	vs GILD
NVSNovartis AG	143.26	+1.75%	$272.29B	21.6	vs GILD

Indexes, lists and sector

Index membership

Appears in lists

Largest Healthcare stocks

Gilead Sciences stock FAQ

What is Gilead Sciences's stock price today?

GILD last traded at $146.85 as of Oct 7, 4:00 PM EDT, up 1.82% on the day. Prices are delayed at least 15 minutes.

Does Gilead Sciences pay a dividend?

Yes. Gilead Sciences pays $3.22 per share annually, a 2.19% yield. The most recent dividend of $0.82 had an ex-dividend date of Sep 15, 2026.

When is Gilead Sciences's next earnings date?

Gilead Sciences is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $2.15.

Is Gilead Sciences in the S&P 500?

Yes. Gilead Sciences (GILD) is a constituent of the S&P 500 index.

Who is Gilead Sciences's CEO?

Mr. Daniel Patrick O'Day is the chief executive officer of Gilead Sciences Inc., which has about 17,000 employees.

Has GILD ever split its stock?

Yes. The most recent GILD stock split was a 2-for-1 split on Jan 28, 2013, one of 5 splits on record.

What is the GILD 52-week high?

The 52-week high for GILD is $157.29 and the 52-week low is $114.02. The stock is currently 6.6% below its high.